Diplopia,Facial Weakness,and Ascending Paresthesia in a Young Male

Abstract

Get full access to this article

View all access options for this article.

References

Yeshokumar

Narula

Banwell

Pediatric multiple sclerosis. Curr Opin Neurol. 2017;30:216-221. doi:10.1097/WCO.0000000000000452

Banwell

Krupp

Kennedy

, et al. Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol. 2007;6:773-781. doi:10.1016/S1474-4422(07)70196-5

Alroughani

Boyko

Pediatric multiple sclerosis: a review. BMC Neurol. 2018;18:27. doi:10.1186/s12883-018-1026-3

Chitnis

Pediatric central nervous system demyelinating diseases. Continuum (Minneap Minn). 2019;25:793-814. doi:10.1212/CON.0000000000000730

Deiva

Absoud

Hemingway

, et al. Acute idiopathic transverse myelitis in children: early predictors of relapse and disability. Neurology. 2015;84:341-349. doi:10.1212/WNL.0000000000001179

Thompson

Banwell

Barkhof

, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162-173. doi:10.1016/S1474-4422(17)30470-2

Krupp

Tardieu

Amato

, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler. 2013;19:1261-1267.

Wong

de Mol

van der Vuurst de Vries

, et al. Real-world validation of the 2017 McDonald criteria for pediatric MS. Neurol Neuroimmunol Neuroinflamm. 2019;6:e528.

Fadda

Brown

Longoni

, et al. MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study. Lancet Child Adolesc Health. 2018;2:191-204.

10.

Hacohen

Brownlee

Mankad

, et al. Improved performance of the 2017 McDonald criteria for diagnosis of multiple sclerosis in children a real-life cohort. Mult Scler. 2020;26:1372-1380.

11.

Harding

Williams

Willis

, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol. 2019;76:536-541. doi:10.1001/jamaneurol.2018.4905